Allogenic γδ T cell and tumor cell fused vaccine for enhanced immunotherapeutic efficacy of osteosarcoma

Publication date: Available online 26 December 2018Source: Journal of Bone OncologyAuthor(s): Yitian Wang, Jian Zhu, Wei Yu, Junjie Wang, Kaishun Xia, Chengzhen Liang, Huimin TaoAbstractHuman γδ T cells have displayed the promising roles in cancer immunity through cytokine secretion and cytotoxic activity. Researches have implicated their principal characteristics as the antigen presentation cells. How to improve γδ T cells' immunotherapeutic effect as the cell vaccine is still a great challenge. Herein, we explore the human γδ T cell and tumor cell fused vaccine for enhanced immunotherapeutic efficacy of osteosarcoma. The fusion cell vaccine was prepared by chemical fusion between human γδ T cells and inactive osteosarcoma Saos-2 cells. The fusion process was confirmed by microcopy observation, and flow cytometry analysis further validated the antigen presenting functions of the fusion cells. Moreover, the immunotherapeutic potential of the fusion cells was then verified via cytotoxicity assay and cytokine release detection. Our study provided novel immunotherapeutic strategy for patients with osteosarcoma, which merits further practice in the near future.
Source: Journal of Bone Oncology - Category: Cancer & Oncology Source Type: research